OMICXIQ.AI Trademark

Trademark Overview

On Friday, August 1, 2025, a trademark application was filed for OMICXIQ.AI with the United States Patent and Trademark Office. The USPTO has given the OMICXIQ.AI trademark a serial number of 99315178. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, June 23, 2026. This trademark is owned by ThinkBio.Ai., Inc.. The OMICXIQ.AI trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Development of pharmaceuticals for cell and gene therapies
omicxiq.ai

General Information

Serial Number99315178
Word MarkOMICXIQ.AI
Filing DateFriday, August 1, 2025
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, June 23, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 23, 2026

Trademark Statements

Goods and ServicesDevelopment of pharmaceuticals for cell and gene therapies
Pseudo MarkOMICXIQ ARTIFICIAL INTELLIGENCE

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 1, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameThinkBio.Ai., Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressOntario, CA 91764
US
Party NameThinkBio.Ai., Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressOntario, CA 91764
US

Trademark Events

Event DateEvent Description
Friday, August 1, 2025NEW APPLICATION ENTERED
Friday, August 1, 2025APPLICATION FILING RECEIPT MAILED
Wednesday, December 10, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 16, 2025ASSIGNED TO EXAMINER
Tuesday, January 6, 2026NON-FINAL ACTION WRITTEN
Tuesday, January 6, 2026NON-FINAL ACTION E-MAILED
Tuesday, January 6, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 6, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 6, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 6, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, February 22, 2026NON-FINAL ACTION WRITTEN
Sunday, February 22, 2026NON-FINAL ACTION E-MAILED
Sunday, February 22, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 23, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 23, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 23, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 23, 2026FINAL REFUSAL WRITTEN
Monday, March 23, 2026FINAL REFUSAL E-MAILED
Monday, March 23, 2026NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, March 24, 2026TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, March 24, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 24, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 22, 2026NON-FINAL ACTION WRITTEN
Wednesday, April 22, 2026NON-FINAL ACTION E-MAILED
Wednesday, April 22, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 22, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 22, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 22, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 27, 2026EXAMINERS AMENDMENT -WRITTEN
Wednesday, May 27, 2026EXAMINERS AMENDMENT E-MAILED
Wednesday, May 27, 2026EXAMINER'S AMENDMENT ENTERED
Wednesday, May 27, 2026NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, May 27, 2026APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 17, 2026NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 23, 2026PUBLISHED FOR OPPOSITION
Tuesday, June 23, 2026OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Related Keywords

omicxiq therapies gene cell pharmaceuticals development